Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms 

Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms 


US President Donald Trump speaks during a cabinet meeting in the Cabinet Room of the White House in Washington, DC, on April 30, 2025.

Jim Watson | Afp | Getty Images

President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build new production sites stateside. 

The order comes ahead of Trump’s planned tariffs on pharmaceuticals imported into the U.S. Those potential levies – and efforts to build goodwill with the President – have already fueled a fresh wave of domestic manufacturing investments from drugmakers such as Eli Lilly, Johnson & Johnson and AbbVie

It’s unclear when Trump could announce pharmaceutical-specific tariffs, or if the new executive order changes those plans. But the Trump administration disclosed in April that it had opened a so-called Section 232 investigation into how importing certain pharmaceuticals affects national security — a move widely seen as a prelude to initiating tariffs on drugs. 

Some pharmaceutical companies are starting to push back on Trump’s plans. For example, Pfizer CEO Albert Bourla said last week that the tariff threat is deterring the company from making further U.S. investments in research and development and manufacturing.

U.S. manufacturing in the pharmaceutical industry has shrunk significantly in recent decades. Production of most of the so-called active ingredients in medicines has moved to China and other countries, largely due to lower costs for labor and other parts of the process, according to the Food and Drug Administration.

The U.S. imported $203 billion in pharmaceutical products in 2023 alone, with 73% coming from Europe, primarily Ireland, Germany and Switzerland, according to analysis conducted by consulting firm EY. 

Reshoring manufacturing can help make the drug supply chain more robust, decreasing the risk of disruptions, according to an April release from GlobalData, a data and analytics company. Still, it could elevate production costs and drug prices, raising affordability concerns, GlobalData said.



Source

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Health

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Competition in […]

Read More
CDC vaccine panel holds first meeting since RFK Jr. put immunization critics in place
Health

CDC vaccine panel holds first meeting since RFK Jr. put immunization critics in place

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia. Tami Chappell | Reuters A crucial government panel of vaccine advisors will hold its first meeting Wednesday since Health and Human Services Secretary Robert F. Kennedy Jr. appointed several vaccine critics to the group.  Earlier this month, Kennedy in […]

Read More
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Health

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%

The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company’s sales […]

Read More